高级搜索

重组人肿瘤坏死因子相关凋亡诱导配体蛋白(rhTRAIL) 逆转人肺腺癌细胞A549/ CDDP耐顺铂效应的初步研究

张梅春, 胡成平, 陈 琼, 杨红忠, 刘洪波

张梅春, 胡成平, 陈 琼, 杨红忠, 刘洪波. 重组人肿瘤坏死因子相关凋亡诱导配体蛋白(rhTRAIL) 逆转人肺腺癌细胞A549/ CDDP耐顺铂效应的初步研究[J]. 肿瘤防治研究, 2005, 32(07): 398-340. DOI: 10.3971/j.issn.1000-8578.1602
引用本文: 张梅春, 胡成平, 陈 琼, 杨红忠, 刘洪波. 重组人肿瘤坏死因子相关凋亡诱导配体蛋白(rhTRAIL) 逆转人肺腺癌细胞A549/ CDDP耐顺铂效应的初步研究[J]. 肿瘤防治研究, 2005, 32(07): 398-340. DOI: 10.3971/j.issn.1000-8578.1602
ZHANG Mei-chun, HU Cheng-ping, CHEN Qiong, YANGHong-zhong, LIU Hong-bo. Reversing Effect of rhTRAIL on Cisplatin-resistant Human Lung Adenocarcinma Cell Line A549/ CDDP[J]. Cancer Research on Prevention and Treatment, 2005, 32(07): 398-340. DOI: 10.3971/j.issn.1000-8578.1602
Citation: ZHANG Mei-chun, HU Cheng-ping, CHEN Qiong, YANGHong-zhong, LIU Hong-bo. Reversing Effect of rhTRAIL on Cisplatin-resistant Human Lung Adenocarcinma Cell Line A549/ CDDP[J]. Cancer Research on Prevention and Treatment, 2005, 32(07): 398-340. DOI: 10.3971/j.issn.1000-8578.1602

重组人肿瘤坏死因子相关凋亡诱导配体蛋白(rhTRAIL) 逆转人肺腺癌细胞A549/ CDDP耐顺铂效应的初步研究

详细信息
    通信作者:

    张梅春

  • 中图分类号: R734. 2

Reversing Effect of rhTRAIL on Cisplatin-resistant Human Lung Adenocarcinma Cell Line A549/ CDDP

More Information
    Corresponding author:

    ZHANG Mei-chun

  • 摘要: 目的 探讨重组人可溶性肿瘤坏死因子相关诱导配体蛋白(rhTRAIL)对人肺腺癌细胞A549/CDDP耐顺铂的逆转效应。方法 以顺铂(CDDP)联合不同浓度的rhTRAIL处理A549/CDDP,以四氮唑噻蓝盐(MTT)比色法检测顺铂的半效抑制浓度IC50并计算耐药逆转倍数RI。结果 rhTRAIL体外可明显降低A549/CDDP对CDDP的IC50提高耐药逆转倍数。结论 rhTRAIL体外可较大程度逆转A549/CDDP细胞对CDDP的耐药性,有望成为抗耐药性肺癌的一种新的生物制剂。
    Abstract: Objective  To explore the reversal effect s of rhTRAIL on the multidrug-resistant cell line A549/ CDDP. Methods  A549/ CDDP was treated with combinations of rhTRAIL. IC50 values and reversing drug-resistance index (RI) of the chemotherapeutic drug were analyzed by MTT assay. Results  After treated with rhRRAIL, IC50 values of CDDP of A549/ CDDP cell line were reduced very significantly ( P < 0. 01), while RI augmented significantly ( P < 0. 05) . Conclusion  rhTRAIL has reversal effects on multi-drug resistant cell line A549/ CDDP, which is a very promising biological drug for drug resistant lung cancer.
计量
  • 文章访问数:  2651
  • HTML全文浏览量:  63
  • PDF下载量:  888
  • 被引次数: 0
出版历程
  • 收稿日期:  2004-07-19
  • 修回日期:  2004-12-15
  • 刊出日期:  2005-07-04

目录

    LIU Hong-bo

    1. On this Site
    2. On Google Scholar
    3. On PubMed

    /

    返回文章
    返回
    x 关闭 永久关闭